Precision launches new tumor profiling product

Precision Therapeutics, Inc. announced that the launch of a new product line, BioSpeciFx®, will help further the personalization of cancer treatments. BioSpeciFx® is composed of carefully selected sets of well validated and clinically useful biomarker tests that identify critical molecular targets within a patient's cell.  By using the information generated by BioSpeciFx® in combination with Precision's sophisticated drug response marker ChemoFx®, physicians may gain a more complete understanding of a patient's tumor.

When combined, both products offer a complementary sum of information which will enable physicians to look at both the relevant molecular targets as well as the synergistic activity of drug combinations on the entire cell.  BioSpeciFx® provides proteomic and genomic information, while ChemoFx® takes into account all of the functional characteristics of a tumor including those not captured by biomarker testing, providing both sensitivity and resistance information.

"The Comprehensive Tumor Profile developed by Precision presents the most complete offering available to cancer patients today, because it integrates both genomic and proteomic information with the functional profiling of ChemoFx®," says Sean McDonald, CEO of Precision Therapeutics.  "We are very excited to provide physicians with a closer look at each patient's tumor as we continue to develop products aimed at personalizing treatments for cancer patients."

Source:

Precision Therapeutics

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research identifies key factors in initiating tumor dormancy